SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$3.20 -0.53%

-$0.02 today

Market cap
$288.28M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 0.89M

Average 0.76M

SABS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

SAB Biotherapeutics, Inc.NASDAQ: SABS

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit turns positive

Q2 FY2026 gross profit was $0, compared with -$822K a year earlier. Trailing-twelve-month gross profit was -$2.28M.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$570.36K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$3.08M+11.2% YoY
LTMJun 2026
-$2.28M+77.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+11.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(3.08M) USD
Year-over-year change
+11.2%

Gross Profit vs competitors

How SABS compares with its peers on the latest reported figures

  • SABS's LTM Jun 2026 gross profit of -$2.28M is the lowest of the 5 companies compared; the peer median is $16.63M.
  • Its year-over-year change of +77.4% is the 3rd highest of 4, against a peer median of +545.5%.
SABS Competitors Peer median
Gross Profit for SABS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$53.38M +14926.4%+100.2%99.3%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$33.27M +545.5%+57.0%89.5%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ———
BOLDBoundless Bio, Inc.LTM Mar 2026-$1.22M -359.6%——
SABSSAB Biotherapeutics, Inc.LTM Jun 2026-$2.28M +77.4%——
Peer median (excluding SABS) $16.63M+545.5%+78.6%94.4%

Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.88M23.9M2.24M1.32M0
Cost of Revenue1.65M3.29M3.75M4.79M3.08M
Gross Profit59.22M20.61M(1.51M)(3.47M)(3.08M)
Gross Margin97.3%86.2%-67.3%-262.4%—
Research & Development57.18M36.44M16.52M30.16M34.35M
Selling, General & Admin17.09M16.38M23.8M9.28M14.6M
Operating Expenses72.62M49.53M36.57M39.44M45.87M
Depreciation & Amortization1.65M3.29M3.75M4.79M3.08M
EBITDA(15.2M)(15.12M)(38.13M)(28.99M)16.6M
EBITDA Margin-25.0%-63.3%-1703.1%-2192.5%—
Operating Income(13.39M)(28.92M)(38.08M)(42.91M)(48.95M)
Operating Margin-22.0%-121.0%-1700.5%-3244.9%—
Interest Income23.12K71.07K584.97K1.29M1.43M
Interest Expense294.46K301.58K315.28K318.4K240.66K
Other Income / Expenses(3.75M)10.2M(4.12M)8.81M62.23M
Income Before Tax(17.15M)(18.72M)(42.19M)(34.11M)13.27M
Pre-Tax Margin-28.2%-78.3%-1884.5%-2579.0%—
Income Tax Expense025.63K000
Net Income(17.15M)(18.74M)(42.19M)(34.11M)13.27M
Net Margin-28.2%-78.4%-1884.5%-2579.0%—
EPS (Basic)(3.94)(4.31)(7.64)(3.68)0.22
EPS (Diluted)(6.30)(4.31)(7.64)(3.68)(0.79)
Weighted Avg Shares4.35M4.35M5.52M9.26M19.31M
Weighted Avg Shares (Diluted)2.73M4.35M5.52M9.26M61.34M

SAB Biotherapeutics, Inc.

NASDAQ:SABS

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.